Kits represent 57.0% of product sales and infectious diseases account for 58.0% within the indication segment in 2026. The nucleic acid testing market was valued at USD 4.2 billion in 2025, is projected to reach USD 6.9 billion by 2036 and is forecast to post a 4.6% CAGR between 2026 and 2036.